Vineet Laboratories Limited (VINEETLAB.BO)
Vineet Laboratories Limited operates in the Chemicals industry of the Basic Materials sector, headquartered in Hyderabad, TS, IN. The stock last traded at $37.50, down 2.24% on the session, giving a market capitalisation of $355.6M. Its beta of 0.24 implies it has historically moved less than the broad market.
Established in 2016 and based in Hyderabad, India, Vineet Laboratories Limited specializes in the exploration, development, production, and marketing of active pharmaceutical ingredients (APIs) and specialty chemicals across India. The company's product offerings encompass key intermediates for various APIs, such as lopinavir, ritonavir, efavirenz, nadolol, glimepiride, celecoxib, and olanine, alongside a selection of other API precursors. Furthermore, they provide a diverse array of fine chemicals and laboratory reagents, including, but not limited to, isopropyl-beta-d-thiogalactopyranoside, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde.
Vineet Laboratories Limited is most often compared with the following Basic Materials names: